Topical bromfenac versus prednisolone: post cataract surgery safety and efficacy

Harish R. Trivedi, Harsha Maheshwari


Background: Cataract surgery can result in postoperative inflammation which increases the risk of complications like increased intraocular pressure (IOP), uveitis and cystoid macular oedema. We aim to evaluate the effectiveness of topical non-steroidal anti-inflammatory drug bromfenac and topical prednisolone in controlling intraocular inflammation after uncomplicated cataract surgery and compare intraocular pressure (IOP) differences, degrees of anterior chamber inflammation and macular oedema between two different treatments.

Methods: 100 patients undergoing manual small incision cataract surgery with PMMA posterior chamber intraocular lens implantation were randomly assigned to receive either Bromfenac (0.09%) eye drops or prednisolone acetate (1%) eye suspension as their postoperative anti-inflammatory medication with 50 cases in each group. The patients were examined at the day 1, day 7, day 15, and day 30 after surgery. Postoperative inflammation was evaluated subjectively by intraocular pressure, slit-lamp assessment of signs of inflammation in the form of aqueous cells and flare and optical coherence tomography to rule out post-operative macular oedema.

Results: Both the drugs are equally effective in controlling post-operative inflammation and post-operative cystoid macular oedema.

Conclusions: Bromfenac (0.09%) is an effective drug in controlling ocular inflammation after un-complicated cataract surgery having effect similar to topical Prednisolone acetate (1%) with minimal side effects and less frequent dosing.


Bromfenac, Cataract, Inflammation, Prednisolone

Full Text:



Tsui PH, Huang CC, Zhou Q, Shung KK. Cataract measurement by estimating the ultrasonic statistical parameter using an ultrasound needle transducer: an in vitro study. Physiol Meas. 2011;32:513-22.

Resnikoff S, Pascolini D, Etyaale D. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-51.

Baltussen R, Sylla M, Mariotti SP. Cost-effectiveness analysis of cataract surgery: a global and regional analysis. Bull World Health Organ. 2004;82:338-45.

Thylefors B. A simplifi ed methodology for the assessment of blindness and its main causes. World Health Stat Q. 1987;40:129-41.

Minassian DC, Mehra V. 3.8 Million blinded by cataract each year: Projections from the first epidemiological study of incidence of cataract blindness in India. Br J Ophthalmol. 1990;74:341-3.

Jose R, Bachani D. Performance of cataract surgery between April 2002 and March 2003. NPCB-India. 2003;2:2.

Resnikoff S, Pascolini D, Etyaale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82:844-51.

Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Survey of Ophthalmol. 1992;36(4):259-84.

Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular oedema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25:1492-7.

Gulkilik G, Kocabora S, Taskapili M, Engin G. Cystoid macular oedema after phacoemulsification: risk factors and effect on visual acuity. Can J Ophthalmol. 2006;41:699-703.

Henderson BA, Kim JY, Ament CS, Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema; Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550-8.

Prostaglandins, Leukotrienes (Eicosanoids) and Platelet Activating Factor. KD Tripathi, Essentials of Medical Pharmacology 7th edition; 1995.

Kim AJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology; Major review. Surv Ophthalmol. 2010;55:108-33.

Clark AF, Wilson K, Kater AW, Allingham RR, Cartney MD. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995; 36:478-89.

Daien V, Papinaud L, Domerg C, Lacombe S, Daures JP, Villain M. Incidence and characteristics of cystoid macular edema after cataract surgery. Ophthalmology. 2016;123(3):663-4.

Park’s Textbook of Preventive and Social Medicine, 25th edition; 1995.

Dandona L, Dandona R, Anand R, Srinivas M, Rajashekar V. Outcome and number of cataract surgeries in India: policy issues for blindness control. .Clin Exp Ophthalmol. 2003;31(1):23-31.

Pichhadze R, Blumenthal EZ. Steroid induced glaucoma. Harefuah. 2003;142(2):137-40.

Pleyer U, Paul G, Ursell, Paolo R. Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same. Ophthalmol Ther. 2013;2(2):55-72.

Duong HQ, Westfield KC, Singleton IC, Comparing Three Post-Op Regiments for Management of Inflammation Post Uncomplicated Cataract Surgery. ‘Are Steroids Really Necessary?’. J Clin Exp Ophthalmol, 2011;2:163.

Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86:1380-4.

Misra S, Gaydhankar S, Mehta R. Comparative evaluation of the anti-inflammatory effect of topical 0.1% dexamethasone sodium and topical 1% prednisolone acetate eye drops after small incision cataract surgery in Indian eyes. DJO. 2012;22:263-6.

Schoenwald RD, Boltralik JJ. A bioavailability of comparison in rabbits of two steroids formulated as high viscosity gels and reference aqueous preparation. Invest Ophthalmol Vis Sci. 1979;18:61-6.

Ophthalmology by the American Academy of Ophthalmology. 2014;121:1915-24.

Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR. Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology. 2007;114:1653-62.

Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother. 2006;7(1):99-107.

Ghee CN, Dean S, Meyer DH. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25:33-55.

Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1-11.

Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89-98.

Cho H, Wolf KJ, Wolf EJ, Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthal. 2009;3:199-210.

Keith AW, Amy JE. Management of ocular inflammation following routine cataract surgery-Topical corticosteroid (Prednisolone) Vs Topical Non-steroidal (Bromfenac). US Ophthalmic Review. 2011;4(2):97-100.

Natung, Tanie. Normal Macular Thickness in Healthy Indian Eyes Using Spectral Domain Optical Coherence Tomography. Asia-Pacific J Ophthal. 2016;53:176-9.

Perente I, Utine CA, Ozturker C. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res. 2007;32:241-7.

Chinchurreta AM, Lorenzo M, Rivas RF, Caso PE, Garcia VA, Ofta GC, et al. Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular oedema after phacoemulsification. Int J Ophthalmol. 2018;11(7):1210-6.

Hyun KJ, Beom SW, Kyoung YS, Jeihoon L. Comparison of 1% Prednisolone and 0.1% Bromfenac Solutions for Preventing Macular Edema after Cataract Surgery. J Korean Ophthalmol Soc. 2016;57(12):1834-9.